

Product Data Sheet

Tetrahydrozoline

Cat. No.: HY-B0556 CAS No.: 84-22-0 Molecular Formula: $C_{13}H_{16}N_2$


Molecular Weight: 200.28

Target: Adrenergic Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: -20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (499.30 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.9930 mL	24.9650 mL	49.9301 mL
	5 mM	0.9986 mL	4.9930 mL	9.9860 mL
	10 mM	0.4993 mL	2.4965 mL	4.9930 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.48 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.48 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an α -adrenergic agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion ^{[1][2]} .
In Vitro	Tetrahydrozoline (0.05% HCl-tetrahydrozoline diluted with DMEM to 1:20 concentration; 24 hours) induces the synthesis of collagen types I and III in primary human gingival fibroblasts ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. E Kisilevsky, et al. Anterior and posterior segment vasculopathy associated with long-term use of tetrahydrozoline. CMAJ. 2018 Oct 9;190(40):E1208.

$\hbox{\cite{thm-peak} Peak, et al. Determination of tetrahydrozoline in urine and blood using gas chromatolic properties of the properties o$	graphy-mass spectrometry (GC-MS). Methods Mol Biol. 2010;603:501-8.			
[3]. Danuta Nowakowska, et al. In vitro effects of vasoconstrictive retraction agents on primary human gingival fibroblasts. Exp Ther Med. 2020 Mar; 19(3): 2037-2044.				
[5]. Bunda Howakowska, et al. III vido eneces of vasoconstrictive retraction agents on primary	Trainian gingivar no obtacts. Exp Ther fred. 2020 mar, 13(0), 2007 2011.			
Caution: Product has not been fully validated for medical applications. For research use only.				
Tel: 609-228-6898 Fax: 609-228-5909	E-mail: tech@MedChemExpress.com			
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA				

Page 2 of 2 www.MedChemExpress.com